PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Committee Opinion No. 713: Antenatal Corticosteroid Therapy for Fetal Maturation.

Abstract Corticosteroid administration before anticipated preterm birth is one of the most important antenatal therapies available to improve newborn outcomes. A single course of corticosteroids is recommended for pregnant women between 24 0/7 weeks and 33 6/7 weeks of gestation who are at risk of preterm delivery within 7 days, including for those with ruptured membranes and multiple gestations. It also may be considered for pregnant women starting at 23 0/7 weeks of gestation who are at risk of preterm delivery within 7 days, based on a family's decision regarding resuscitation, irrespective of membrane rupture status and regardless of fetal number. Administration of betamethasone may be considered in pregnant women between 34 0/7 weeks and 36 6/7 weeks of gestation who are at risk of preterm birth within 7 days, and who have not received a previous course of antenatal corticosteroids. A single repeat course of antenatal corticosteroids should be considered in women who are less than 34 0/7 weeks of gestation who are at risk of preterm delivery within 7 days, and whose prior course of antenatal corticosteroids was administered more than 14 days previously. Rescue course corticosteroids could be provided as early as 7 days from the prior dose, if indicated by the clinical scenario. Continued surveillance of long-term outcomes after in utero corticosteroid exposure should be supported. Quality improvement strategies to optimize appropriate and timely antenatal corticosteroid administration are encouraged.
PMID
Related Publications

Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth.

Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth.

Committee Opinion No.677: Antenatal Corticosteroid Therapy for Fetal Maturation.

Committee Opinion No. 677 Summary: Antenatal Corticosteroid Therapy for Fetal Maturation.

Committee Opinion No. 713 Summary: Antenatal Corticosteroid Therapy for Fetal Maturation.

Authors

Mayor MeshTerms

Fetal Membranes, Premature Rupture

Fetal Organ Maturity

Keywords
Journal Title obstetrics and gynecology
Publication Year Start




PMID- 28742678
OWN - NLM
STAT- MEDLINE
DA  - 20170725
DCOM- 20170809
LR  - 20170809
IS  - 1873-233X (Electronic)
IS  - 0029-7844 (Linking)
VI  - 130
IP  - 2
DP  - 2017 Aug
TI  - Committee Opinion No. 713: Antenatal Corticosteroid Therapy for Fetal Maturation.
PG  - e102-e109
LID - 10.1097/AOG.0000000000002237 [doi]
AB  - Corticosteroid administration before anticipated preterm birth is one of the most
      important antenatal therapies available to improve newborn outcomes. A single
      course of corticosteroids is recommended for pregnant women between 24 0/7 weeks 
      and 33 6/7 weeks of gestation who are at risk of preterm delivery within 7 days, 
      including for those with ruptured membranes and multiple gestations. It also may 
      be considered for pregnant women starting at 23 0/7 weeks of gestation who are at
      risk of preterm delivery within 7 days, based on a family's decision regarding
      resuscitation, irrespective of membrane rupture status and regardless of fetal
      number. Administration of betamethasone may be considered in pregnant women
      between 34 0/7 weeks and 36 6/7 weeks of gestation who are at risk of preterm
      birth within 7 days, and who have not received a previous course of antenatal
      corticosteroids. A single repeat course of antenatal corticosteroids should be
      considered in women who are less than 34 0/7 weeks of gestation who are at risk
      of preterm delivery within 7 days, and whose prior course of antenatal
      corticosteroids was administered more than 14 days previously. Rescue course
      corticosteroids could be provided as early as 7 days from the prior dose, if
      indicated by the clinical scenario. Continued surveillance of long-term outcomes 
      after in utero corticosteroid exposure should be supported. Quality improvement
      strategies to optimize appropriate and timely antenatal corticosteroid
      administration are encouraged.
CN  - Committee on Obstetric Practice
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
RN  - 0 (Adrenal Cortex Hormones)
RN  - 9842X06Q6M (Betamethasone)
SB  - AIM
SB  - IM
MH  - Adrenal Cortex Hormones/administration & dosage
MH  - Betamethasone/administration & dosage
MH  - Drug Administration Schedule
MH  - Female
MH  - *Fetal Membranes, Premature Rupture
MH  - *Fetal Organ Maturity
MH  - Humans
MH  - Obstetrics/*standards
MH  - Pregnancy
MH  - Prenatal Care/*standards
IR  - El-Sayed YY
FIR - El-Sayed, Yasser Y
IR  - Borders AEB
FIR - Borders, Ann E.B
IR  - Gyamfi-Bannerman C
FIR - Gyamfi-Bannerman, Cynthia
EDAT- 2017/07/26 06:00
MHDA- 2017/08/10 06:00
CRDT- 2017/07/26 06:00
AID - 10.1097/AOG.0000000000002237 [doi]
AID - 00006250-201708000-00058 [pii]
PST - ppublish
SO  - Obstet Gynecol. 2017 Aug;130(2):e102-e109. doi: 10.1097/AOG.0000000000002237.